RVMD Q3 2023 Earnings — Revolution Medicines, Inc. Revenue & Financial Results | Market Cap Arena

RVMDRevolution Medicines, Inc.

$20B

Q3 2023 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$0-100.0% YoY

Gross Profit

$0

Operating Income

-$123M

Net Income

-$108M

EPS (Diluted)

$-0.99

QoQ Revenue Growth

-100.0%

Cash Flow

Operating Cash Flow

-$100M

Free Cash Flow

-$103M

Stock-Based Comp.

$14M

Balance Sheet

Total Assets

$984M

Total Liabilities

$147M

Stockholders' Equity

$837M

Cash & Equivalents

$358M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$0	$3M	-100.0%
Gross Profit	$0	$3M	-100.0%
Operating Income	-$123M	-$77M	-61.0%
Net Income	-$108M	-$73M	-47.9%